Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

7.10USD
23 Feb 2018
Change (% chg)

$0.10 (+1.43%)
Prev Close
$7.00
Open
$7.04
Day's High
$7.11
Day's Low
$6.73
Volume
191,070
Avg. Vol
257,410
52-wk High
$25.11
52-wk Low
$5.91

Chart for

About

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $263.25
Shares Outstanding(Mil.): 37.08
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

Jan 08 2018

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

Dec 11 2017

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

Nov 02 2017

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

Oct 30 2017

BRIEF-NewLink Genetics announces proposed public offering of common stock

* NewLink Genetics announces proposed public offering of common stock

Oct 03 2017

BRIEF-NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet

* NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

Sep 25 2017

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

Sep 25 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,528 +19.00
Pfizer Inc. (PFE.N) $36.26 +0.52
Novartis AG (NOVN.S) CHF79.38 -0.60
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Abbott Laboratories (ABT.N) $59.71 +0.72
Sanofi SA (SASY.PA) €65.05 +0.16
AstraZeneca plc (AZN.L) 4,752.00 -20.00
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00

Earnings vs. Estimates